GLUE Healthcare

Monte Rosa Therapeutics, Inc.

$10.41-2.07%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 888.1M USD
Enterprise value: 305.0M USD
Full-time employees: 173

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity
Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.37 vs a peer median of 0.63)bigger price swings (beta 1.37 vs peers 0.63)

Ranks #1,055 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 73% from December 2022 to July 2026.
Monte Rosa Therapeutics had 73% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Monte Rosa Therapeutics had 73% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Earnings slid into a loss. Loss per share this year after a profit last year.
Monte Rosa Therapeutics made a loss per share in its latest year after a profit the year before.
Stock-based pay is a large cost. Stock pay was 15% of revenue in 2025.
Monte Rosa Therapeutics paid employees $19M in stock in 2025, 15% of its $124M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Monte Rosa Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

StockQuotient Score

25/ 100

Oct 5 25 → Nov 4 25

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-18.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-57.0%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-3.6%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield54.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

3/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

12-month revenue fell 33.1%

Why

Weaker than most peers on:

▼ Revenue growth
▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Earnings per share turned from a profit to a loss33% base weight · Z-score -1.99Sector median: 0.0976 · MAD: 0.2991

3-year revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0584 · MAD: 0.0840

Revenue growth-83.9%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

6/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-633.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -52.59Sector median: 0.0706 · MAD: 0.1217

Return on assets-23.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.65Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-36.2%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.07Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-33.1%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.37

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -2.20Sector median: 0.6250 · MAD: 0.3380

Current ratio10.58×

SEC filings · latest balance sheetReported value33% base weight · Z-score 5.77Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.08×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.70Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Monte Rosa Therapeutics

Is Monte Rosa Therapeutics getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 33.1%. Its overall score is unchanged at 25/100 since Oct 28, 2026.
How is Monte Rosa Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -18.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -18.1% vs peers 1.5% (weaker than 100% of peers).
Is Monte Rosa Therapeutics growing?: More slowly than most of its peers. Growth scores 3/100 against 1,393 healthcare peers. Revenue growth -83.9% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -83.9% vs peers 6.1% (weaker than 100% of peers).
How profitable is Monte Rosa Therapeutics?: Less profitable than most of its peers. Profitability scores 6/100 against 1,393 healthcare peers. Operating margin -633.0% vs a peer median of 7.1% (weaker than 94% of peers).Operating margin -633.0% vs peers 7.1% (weaker than 94% of peers).
How risky is Monte Rosa Therapeutics?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.58× vs a peer median of 2.59× (stronger than 88% of peers).Current ratio 10.58× vs peers 2.59× (stronger than 88% of peers). Beta 1.37 vs a peer median of 0.63 (weaker than 84% of peers).Beta 1.37 vs peers 0.63 (weaker than 84% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 33.1%

Worth watching: Monte Rosa Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	43.0M USD	28.7M USD	−33.1%
Net income (12 months)	−130.0M USD	−161.1M USD	+23.9%
Operating margin	-345.2%	-633.0%	−287.8 pts
Free cash flow (12 months)	−19.7M USD	−32.1M USD	+63.2%
Cash	159.9M USD	90.1M USD	−43.6%
Shares outstanding	84.5M	85.3M	+1.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	—	—	—	-107.3%	-43.8%	▲ 63 pts
Net margin	—	—	—	-96.1%	-31.2%	▲ 65 pts
Return on assets (ROA)	-20.2%	-31.7%	-44.6%	-16.6%	-8.6%	▲ 8.0 pts
Return on equity (ROE)	-21.3%	-40.0%	-75.5%	-32.6%	-16.6%	▲ 16 pts
Free cash flow margin	—	—	—	50.3%	-22.2%	▼ 72 pts
Current ratio	20.96×	10.79×	5.07×	2.40×	6.12×	▲ 155%

GLUE price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquidity and less debt relative to equitylower risk: more liquidity and less debt vs equity

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.37 vs a peer median of 0.63)bigger price swings (beta 1.37 vs peers 0.63)

Ranks #1,055 of 1,157 healthcare companies (bottom 9%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 73% from December 2022 to July 2026.

Monte Rosa Therapeutics had 73% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Monte Rosa Therapeutics had 73% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Earnings slid into a loss. Loss per share this year after a profit last year.

Monte Rosa Therapeutics made a loss per share in its latest year after a profit the year before.

Stock-based pay is a large cost. Stock pay was 15% of revenue in 2025.

Monte Rosa Therapeutics paid employees $19M in stock in 2025, 15% of its $124M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Monte Rosa Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Questions investors ask about Monte Rosa Therapeutics

Is Monte Rosa Therapeutics getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 33.1%. Its overall score is unchanged at 25/100 since Oct 28, 2026.

How is Monte Rosa Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -18.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -18.1% vs peers 1.5% (weaker than 100% of peers).

Is Monte Rosa Therapeutics growing?

More slowly than most of its peers. Growth scores 3/100 against 1,393 healthcare peers. Revenue growth -83.9% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -83.9% vs peers 6.1% (weaker than 100% of peers).

How profitable is Monte Rosa Therapeutics?

Less profitable than most of its peers. Profitability scores 6/100 against 1,393 healthcare peers. Operating margin -633.0% vs a peer median of 7.1% (weaker than 94% of peers).Operating margin -633.0% vs peers 7.1% (weaker than 94% of peers).

How risky is Monte Rosa Therapeutics?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 10.58× vs a peer median of 2.59× (stronger than 88% of peers).Current ratio 10.58× vs peers 2.59× (stronger than 88% of peers). Beta 1.37 vs a peer median of 0.63 (weaker than 84% of peers).Beta 1.37 vs peers 0.63 (weaker than 84% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

43.0M USD

28.7M USD

−33.1%

Net income (12 months)

−130.0M USD

−161.1M USD

+23.9%

Operating margin

-345.2%

-633.0%

−287.8 pts

Free cash flow (12 months)

−19.7M USD

−32.1M USD

+63.2%

Cash

159.9M USD

90.1M USD

−43.6%

Shares outstanding

84.5M

85.3M

+1.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

—

-107.3%

-43.8%

▲ 63 pts

Net margin

—

-96.1%

-31.2%

▲ 65 pts

Return on assets (ROA)

-20.2%

-31.7%

-44.6%

-16.6%

-8.6%

▲ 8.0 pts

Return on equity (ROE)

-21.3%

-40.0%

-75.5%

-32.6%

-16.6%

▲ 16 pts

Free cash flow margin

—

50.3%

-22.2%

▼ 72 pts

Current ratio

20.96×

10.79×

5.07×

2.40×

6.12×

▲ 155%